In this interview, Ergomed’s CFO Richard Barfield talks with Oliver Haslam, Director of Edison Group about: The highlights of Ergomed’s recent trading update, with total H120 revenues increasing by 14.8% to £40.4m How Ergomed has demonstrated significant resilience through the COVID-19 crisis Some of the reasons behind the startling growth in Ergomed’s revenues over the […]
In this interview, Ergomed’s CFO Richard Barfield talks with Oliver Haslam, Director of Edison Group about:
- The highlights of Ergomed’s recent trading update, with total H120 revenues increasing by 14.8% to £40.4m
- How Ergomed has demonstrated significant resilience through the COVID-19 crisis
- Some of the reasons behind the startling growth in Ergomed’s revenues over the last three years and how it intends to maintain that momentum
- An overview of Ergomed’s M&A strategy
- The outlook towards upcoming newsflow